Consideration of Carcinogenicity and Mode of Action Information by an Independent Expert Panel to Support Derivation of No-Significant-Risk-Level Values for Vinyl Acetate Monomer.

Authors

C R Kirman, W Dekant, V L Dellarco, M L Dourson, J E Klaunig, T W Simon, S M Hays

Published in

Regulatory toxicology and pharmacology : RTP. Pages 106170. Jun 27, 2026. Epub Jun 27, 2026.

Abstract

A triple-blinded, independent panel of five experts was engaged to review information on the cancer mode of action (MOA) of vinyl acetate monomer (VAM) to provide input on key decisions for the calculation of No-Significant-Risk-Level (NSRL) values using best available science. Based upon the weight of evidence, the panel expressed a strong preference in using effects observed at the point of contact for the NSRL rather than in using those observed in systemic tissues. None of the systemic endpoints were identified as useful for quantitative risk assessment. A cancer MOA involving cytotoxicity and regenerative cell proliferation was best supported by the weight of evidence (mean score of +3.8±1.1; scale of -5 to +5). In contrast, a cancer MOA involving direct genotoxicity was not supported for VAM (mean score of -3.6±2.0). Separate NSRL values were derived for inhalation and oral routes. Based upon the decisions recommended by the panel at each step of the process, inhalation and oral NSRL values of 20,000 and 110,000 μg/day were calculated, respectively. Confidence in the inhalation and NSRL values was considered high and medium, respectively by the panel. Human exposures at or below these NSRL levels are not expected to pose a significant cancer risk.

PMID:
42364689
Bibliographic data and abstract were imported from PubMed on 28 Jun 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.